Allozyne, Inc. Announces Completion of Phase IA Trial by AZ01, a Long Lasting Interferon B for Treatment of Relapsing Remitting Multiple Sclerosis  
1/11/2011 9:31:01 AM

(BUSINESS WIRE)--ALLOZYNE, Inc. announced today, the completion of its first Phase IA clinical trial in healthy individuals for AZ01, a PEGylated form of human interferon beta-1b which is being developed for the treatment of relapsing remitting multiple sclerosis. The objectives of the Phase IA trial were to assess safety and tolerability profile in addition to defining its pharmacological properties. The results demonstrate that single administrations of AZ01 were well tolerated at all dosage levels tested. In addition, drug serum levels and interferon activity biomarkers were maintained well after administration in the highest dose groups indicating that once a month dosing may be a viable treatment regimen to pursue. In addition to the possibility of monthly dosing convenience, the data suggests that patients treated with AZ01 will experience a reduction in the days per month with flu-like symptoms and minimal to no injection site reactions. A multiple administration Phase IB trial is underway with results to be announced in mid 2011.